These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 38868744)

  • 1. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.
    Andersen KØ; Detlefsen S; Brusgaard K; Christesen HT
    Front Endocrinol (Lausanne); 2024; 15():1351624. PubMed ID: 38868744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
    Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
    J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of Pancreatic Neuroendocrine Tumors.
    Mohindroo C; McAllister F; De Jesus-Acosta A
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 5. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
    Marini F; Giusti F; Tonelli F; Brandi ML
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors.
    Ling C; Hong X; Xu M; Wang Y; Ma X; Cui Y; Jiang R; Cao D; Wu H; Tong A; Zhao Y; Wu W
    Eur J Endocrinol; 2022 May; 187(1):85-90. PubMed ID: 35521758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.
    Soczomski P; Jurecka-Lubieniecka B; Krzywon A; Cortez AJ; Zgliczynski S; Rogozik N; Oczko-Wojciechowska M; Pawlaczek A; Bednarczuk T; Jarzab B
    Front Endocrinol (Lausanne); 2021; 12():681013. PubMed ID: 34122352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.
    Marx SJ; Agarwal SK; Kester MB; Heppner C; Kim YS; Skarulis MC; James LA; Goldsmith PK; Saggar SK; Park SY; Spiegel AM; Burns AL; Debelenko LV; Zhuang Z; Lubensky IA; Liotta LA; Emmert-Buck MR; Guru SC; Manickam P; Crabtree J; Erdos MR; Collins FS; Chandrasekharappa SC
    Recent Prog Horm Res; 1999; 54():397-438; discussion 438-9. PubMed ID: 10548885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms.
    Görtz B; Roth J; Krähenmann A; de Krijger RR; Muletta-Feurer S; Rütimann K; Saremaslani P; Speel EJ; Heitz PU; Komminoth P
    Am J Pathol; 1999 Feb; 154(2):429-36. PubMed ID: 10027401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
    Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
    Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.
    De Jesus-Acosta A; Mohindroo C
    JCO Precis Oncol; 2024 Sep; 8():e2400221. PubMed ID: 39231376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analysis of parathyroid and pancreatic tumors in a patient with multiple endocrine neoplasia type 1 using whole-exome sequencing.
    Kim BY; Park MH; Woo HM; Jo HY; Kim JH; Choi HJ; Koo SK
    BMC Med Genet; 2017 Oct; 18(1):106. PubMed ID: 28969599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches.
    Stevenson M; Lines KE; Thakker RV
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):525-548. PubMed ID: 30098714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARMC5 Alterations in Patients With Sporadic Neuroendocrine Tumors and Multiple Endocrine Neoplasia Type 1 (MEN1).
    Damjanovic SS; Antic JA; Elezovic-Kovacevic VI; Dundjerovic DM; Milicevic IT; Beleslin-Cokic BB; Ilic BB; Rodic GS; Berthon A; Maria AG; Faucz FR; Stratakis CA
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4531-42. PubMed ID: 32901291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
    Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
    Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors.
    Mohindroo C; Baydogan S; Agarwal P; Wright RD; Prakash LR; Mork ME; Klein AP; Laheru DA; Maxwell JE; Katz MHG; Dasari A; Kim MP; He J; McAllister F; De Jesus-Acosta A
    Cancer Prev Res (Phila); 2024 Jul; 17(7):335-342. PubMed ID: 38662083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
    Ishida H; Lam AK
    Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.